About this trial
Down syndrome (DS), the most common genetic cause of intellectual disability, is associated with widespread organ dysfunction, including abnormalities in the autonomic nervous system (ANS). The ANS regulates critical functions such as heart rate (HR) and blood pressure (BP), both essential for maintaining homeostasis and supporting physical activity. Individuals with DS often exhibit blunted HR responses to exercise-typically \~30 beats per minute below expected levels-suggesting reduced sympathetic nervous system (SNS) activity. The SNS governs rapid changes in HR and BP during stress by releasing catecholamines: epinephrine (from the adrenal medulla) and norepinephrine (from sympathetic nerve endings). Despite its importance, SNS function has not been comprehensively assessed among individuals with DS.
This study addresses a critical knowledge gap by evaluating SNS responses to physiological stressors in individuals with DS. The investigators will measure beat-to-beat HR and BP, along with plasma catecholamine levels, in response to sympathetic activation, comparing individuals with DS to age- and sex-matched controls. Understanding the mechanisms of SNS dysfunction in DS is vital, as it likely underlies reduced exercise capacity and contributes to broader clinical challenges. These insights may guide targeted interventions to improve cardiovascular function, physical capacity, and overall quality of life in this understudied population.
Eligibility criteria
Qualifiers
18-50 yrs old and apparently healthy individuals
Ability to understand the study and give assent to participate
Has a study partner who can attend all visits for the individuals with DS, and answer questionnaires, provide consent when necessary
Corrected or non-existent congenital heart disease
Disqualifiers
Hypertension (resting systolic blood pressure [SBP] ≥140 and/or diastolic blood pressure [DBP] ≥90 mmHg) this includes those on medications to treat hypertension
Hypotension (resting BP of <90/60 mmHg)
Cancer in the last six months
Any heart-rate-altering medications or any other medication that may modify metabolic responses
Trial design
Treatments tested in this trial
- Fear Response
- Cold Stress
- Pain Response
- Caffeine
- 12-Hour Fast
- Maximal Dynamic Exercise
Treatment groups
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Linda Crnic Institute for Down Syndrome
Collaborator
GLOBAL Down Syndrome Foundation
Collaborator
University of Colorado Colorado Clinical and Translational Sciences Institute
Collaborator